title: Ovarian stimulation in obese and non-obese polycystic ovary syndrome using a low-dose step-up regimen with two different starting doses of recombinant follicle-stimulating hormone.
abstract: Sixty-seven infertile women with polycystic ovary syndrome (PCOS) were divided into two groups, obese and non-obese, according to their body mass index. Waist-to-hip ratio, insulin resistance, total testosterone and dehydroepiandrosterone sulphate levels were significantly elevated in obese, compared with non-obese, patients. Both groups were treated with a low-dose step-up protocol of recombinant follicle-stimulating hormone (rFSH) with a starting dose of 50 IU/day and, every third day, a 25-IU increase in the dose until the appropriate dose was achieved for each individual, up to a maximum of 175 IU/day. In the obese group only, repeat therapy commenced in the second ovulatory cycle in women who had not become pregnant, however a starting dose of 75 IU/day was then used, with incremental and maximum dose as before. The results of the starting dose of 75 IU/day rFSH were compared with the results of a 50 IU/day rFSH starting dose in the obese group. A starting dose of 50 IU/day rFSH in a low-dose step-up regimen was found to be effective, safe and well-tolerated for inducing follicular development in non-obese infertile women with PCOS. However, for obese PCOS patients, a starting dose of 75 IU/day rFSH is recommended.
authors.affiliation: Department of Obstetrics and Gynaecology, Medical Faculty, Yuzuncu Yil University, Van, Turkey. recepyildizhan@yahoo.com
authors.forename: R
authors.initials: R
authors.lastname: Yildizhan
authors.forename: E
authors.initials: E
authors.lastname: Adali
authors.forename: A
authors.initials: A
authors.lastname: Kolusari
authors.forename: M
authors.initials: M
authors.lastname: Kurdoglu
authors.forename: B
authors.initials: B
authors.lastname: Yildizhan
authors.forename: H G
authors.initials: HG
authors.lastname: Sahin
authors.forename: M
authors.initials: M
authors.lastname: Kamaci
mesh_terms: D000328:Adult; D003687:Dehydroepiandrosterone; D019314:Dehydroepiandrosterone Sulfate / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005260:Female; D043373:Follicle Stimulating Hormone, Human / Q000008:administration & dosage* / Q000097:blood; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy*; D007986:Luteinizing Hormone / Q000097:blood; D009765:Obesity; D006080:Ovarian Follicle / Q000000981:diagnostic imaging / Q000187:drug effects; D010053:Ovary / Q000000981:diagnostic imaging / Q000187:drug effects; D010062:Ovulation Induction / Q000379:methods*; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage; D013739:Testosterone / Q000097:blood; D016896:Treatment Outcome; D014463:Ultrasonography
chemical_list: D043373:Follicle Stimulating Hormone, Human; D011994:Recombinant Proteins; D013739:Testosterone; D003687:Dehydroepiandrosterone; D019314:Dehydroepiandrosterone Sulfate; D007986:Luteinizing Hormone